On January 8, 2026, Ardelyx, Inc. reported unaudited product sales of approximately $87 million for IBSRELA and $28 million for XPHOZAH for Q4 2025, totaling sales of $274 million and $104 million for the full year respectively. The company also stated it had about $265 million in cash and short-term investments as of December 31, 2025, noting these figures are preliminary and subject to adjustments.